XPAR
EQS
Market cap481mUSD
Oct 09, Last price
28.70EUR
1D
1.06%
1Q
-13.94%
Jan 2017
-17.88%
IPO
593.24%
Name
Equasens SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
Related entities
Parent
LA COOPERATIVE WELCOOP
Subsidiaries (2)
EUROPEAN HEALTH LOGISTIC
KAPELSE
Key people
Gregoire de Rotalier
Deputy Chief Executive Officer, Director · since 2024
Denis Supplisson
Chief Executive Officer, Member of the Management Board, Director · since 2023
Daniel Antoine
Director · since 2002
Thierry Chapusot
Chairman of the Board · since 2010
Jean-pierre Dosdat
Director · since 2022
Francois Jacquel
Director · since 2011
Emilie Lecomte
Director · since 2017
Anne Lhote
Director · since 2011
Dominique Pautrat
Director · since 2022
Frederique Schmidt
Finance Director, Director · since 2024
Celine Gris
Independent Director · since 2017
Marie-louise Liger
Independent Director · since 2015
Sophie Mayeux
Independent Director · since 2012
Anne Philipona-hintzy
Independent Director · since 2023
Headquarters & legal address
5 ALLEE DE SAINT-CLOUD
TECHNOPOLE DE NANCY BRABOIS
VILLERS-LES-NANCY 54600
FR
TECHNOPOLE DE NANCY BRABOIS
VILLERS-LES-NANCY 54600
FR
Trading name
PHARMAGEST INTERACTIVE ROUSSEAU INF ORMA
Previous name
PHARMAGEST INTERACTIVE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||